The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a ...

Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity ...

Bain said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare industry.

TOKYO -- Japan's Mitsubishi Chemical Group announced on Friday the agreed sale of its pharmaceutical subsidiary, Mitsubishi Tanabe Pharma, to U.S. investment fund Bain Capital for approximately 510 ...

U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

At 60 years old, Jean-Marc Gilson wasn’t sure if he wanted to be a CEO — again. But Westlake was calling his name.

Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...

Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking ...

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

Health-care companies fell as traders digested a mixed round of earnings for the sector. Hims & Hers is under political pressure amid controversy about the telehealth firm's Super Bowl ad touting an ...

Japan’s Mitsubishi Chemical Group has resolved, at a meeting of the board of directors held today, to transfer its consolidated subsidiary, Mitsubishi Tanabe Pharma (MTPC), which engages in the ...